What Is the First-Line Treatment of Tularemia?
Tularemia is a serious bacterial infection that requires prompt initiation of antimicrobial therapy. The treatment approach is well-defined, with clinical success measured by a clear, objective endpoint.
Clinical Goal
The primary therapeutic target is defervescence — resolution of fever — which typically occurs within approximately 4 days of initiating appropriate treatment.
Treatment Approach
First-line management relies on antimicrobial monotherapy. Multiple antibiotic options are recommended across all clinical forms of the disease, with selection guided by patient age, clinical setting, and presentation.
References
- All forms of tularemia, including ulceroglandular, pneumonic, and typhoidal disease, can be treated with ciprofloxacin, levofloxacin, gentamicin, or doxycycline.
- Although defervescence occurred within 4 days of treatment, ciprofloxacin was discontinued in two (16.7%) children on days 3 and 7 of treatment because of development of a rash.
- All five patients treated with levofloxacin monotherapy rapidly defervesced within 96 hours of treatment initiation and survived.